Recent Finacing
Recent Raise
ImmPrev Bio develops a diagnostic to identify high anti-flagellin Crohn’s patients and a concomitant metabolic checkpoint inhibition therapy, leveraging UAB-licensed patents and CRO partnerships for IND-enabling studies.
Focus Areas
Recent Investors
Funding round
Investor